22 December 2019 in Oncohematology
Objective. The possibilities of ultrasound elastography of the lymph nodes as an additional technique for the intermediate control of treatment of patients with Hodgkin’s lymphoma are determined.Materials and methods. A prospective study included patients with a diagnosis of classical Hodgkin’s lymphoma with affected superficial lymph nodes. Patients underwent ultrasound elastography (compression elastography and shear wave elastography) of the enlarged lymph nodes before treatment and after two cycles of chemotherapy. The reasons for the ultrasound examination of superficial lymph nodes after the second chemotherapy cycle were: an earlier ultrasound examination with revealed changes in the superficial lymph nodes (in 100% of cases), preservation of the palpable formation in the projection of the superficial lymph nodes (in 56.9% of cases). Before ultrasound elastography of the studied group of patients, the positive dynamics after two cycles of chemotherapy was confirmed by PET/CT (Deauville scale 2—3).Results and conclusion. According to strain elastography, stiff heterogeneous (third type of elastogram) and stiff structure (fourth type of elastogram) of affected lymph nodes were noted in 53.5 and 42.3% of cases, respectively, before treatment. After two cycles of chemotherapy, these types of elastogram were 52.1 and 43.7% of cases, respectively. According to the results of shear wave elastography before and after treatment, a decrease in the average shear wave velocity in the affected lymph nodes from 2.67 + 0.69 to 2.21 + 0.40m/s (p = 0.000003) was revealed.
22 June 2023 in Almanac of Clinical Medicine
ГЮГривцова Людмила Юрьевна
+1
Despite their B cell origin, Reed-Berezovsky-Sternberg tumor cells (RBS) in classic Hodgkin's lymphoma (cHL) demonstrate an absolutely unique phenotype. Immunohistochemistry of RBS cells is positive for CD15 antigen in most of cases, CD30, PAX-5; they do not express the T cell antigen CD3, В cell CD19, and in most cases are negative for the B cell antigen CD20, as well as for common leukocyte antigen CD45. Taking into account such unequivocal immunophenotype, RBS cells can be identified by multiparameter flow cytometry. Thus, J.R. Fromm et al. (2006, 2014) have convincingly shown the possibility to identify RBS cells in a puncture and/or biopsy sample of lymphatic nodes in cHL and were of the fair opinion that such rather simple and reproducible technique as flow cytometry could be an additional diagnostic instrument in cHL. We have tested the technique proposed by J.R. Fromm et al. for the assessment of lymphatic node involvement in cHL and used 8 to 10-parameter flow cytometry for detection RBS cells in cHL in 8 biopsy samples of a lymphatic node, and confirmed the feasibility to identify RBS cells by high performance flow cytometry. We also performed morphological and immunohistochemical assessment of the biopsy samples of lymphatic nodes from patients with suspected cHL. The study included clinical cases with immunohistochemically confirmed cHL (n = 8), and the control samples were from those with other diagnoses than Hodgkin's lymphoma. In all cases of cHL we found RBS cells. In future we plan to analyze larger case samples by flow cytometry.
12 September 2023 in Oncohematology
Hodgkin’s lymphoma (HL) is a unique lymphoma of b-cell origin, the tumor cells of which have lost the expression of main b-cell antigens. The standard immunophenotype of the tumor substrate, according to immunohistochemical studies, is characterized by the expression of such markers as CD15, CD30 and PAX-5, while tumor cells have a negative expression of CD3, CD19 and in most cases also CD20 and CD45 (or express this antigen rather weakly). The knowledge gained in recent years has increased the effectiveness of diagnosis, prognosis and treatment of LH. Flow cytometry, as a method of immunophenotyping in classical LH, was practically not used due to the difficulty of distinguishing single reed–sternberg–berezovsky tumor cells (RSB) and the tumor microenvironment (reactive background), which is very rich in cellular elements and is represented by T cells, B cells, eosinophils, histiocytes and plasma cells. However, in the recent past, several studies have successfully attempted to identify rsb cells using multiparameter flow cytometry during aspiration with a thin needle or biopsy of lymph node tissue to confirm or supplement immunohistochemical staining during primary diagnosis. Taking into account the very characteristic immunophenotype of RSB cells, the flow cytometry may become an additional diagnostic method of classical LH in the future. In this review, we summarize the data on the possibility of using the flow cytometry as an additional clinical diagnostic option in the primary diagnosis of classical LH.
20 September 2023 in MD-Onco
Multiple myeloma (MM) is a B-cell lymphoproliferative disorder. Its morphological substrate is plasma cells producing monoclonal immunoglobulin. Monoclonal light chains damage nephrons leading to development of acute kidney failure (AKF) which can be diagnosed at MM onset, recurrence, or progression. Dialysis-dependent kidney failure (DDKF) is associated with worse prognosis and decreased overall survival. Currently, the standard of MM therapy complicated by moderate and severe AKF is programs including bortezomib. According to the results of completed trials, achievement of hematological response plays the main role in AKF resolution, therefore, the use of new highly effective regimens of antitumor drug therapy is recommended. Despite the results of large clinical trials showing the effectiveness of daratumumab in therapy of patients with MM, data on its use in patients with newly diagnosed MM complicated by DDKF who are candidates for autologous hematopoietic stem cell transplant are limited. A case of daratumumab therapy (as monotherapy and in combination with lenalidomide, dexamethasone) of a 38-year-old female patient with MM complicated by DDKF and significant adverse events developed during previous short-term treatment with bortezomib is presented. The achieved hematological response (partial remission, absence of minimal residual disease), satisfactory somatic condition, as well as favorable daratumumab safety profile allowed to consider the patient for autologous hematopoietic stem cell transplant and increased the probability of improved renal response with subsequent cancellation of hemodialysis.
1 September 2024 in Oncohematology
Background. The study of bone marrow involvement is a necessary step in disease staging, both in non-Hodgkin lymphomas and in the case of Hodgkin lymphoma (HL). The standard assessment of bone marrow lesion is carried out based on immunohistochemical examination of bone marrow trepanobioptate, and recently computer technologies (positron emission tomography combined with computed tomography) have been introduced to assess bone marrow involvement. At the same time, immunological methods for detecting tumor cells using multicolor flow cytometry are more available. In addition, they allow for detailed study of the tumor bone marrow microenvironment.Aim. To evaluate the immunomorphological features of bone marrow in HL and the possibility of identifying specific bone marrow lesions using flow cytometry.Materials and methods. The study included the analysis of 107 bone marrow samples. The samples were obtained from 107 patients with various variants of classical HL, diagnosed and treated at the Lapino Clinical Hospital and the P.A. Herzen Moscow State Medical Institute from 2018 to 2022.Results. The features of bone marrow lymphocytes subpopulation in patients with classical HL are shown.Conclusion. An immunological assessment of bone marrow involvement degree was carried out, data from flow cytometry and immunohistochemical examination of trephine biopsy specimens during primary diagnosis were compared, and the features of bone marrow lymphocytes subpopulation were evaluated. The interrelation of these factors at the diagnostic stage in classical variants of HL was studied. At the end of treatment, the primary immunological data (the degree of bone marrow involvement) were compared with the results of the positron emission tomography combined with computed tomography.
1 August 2022 in Head and Neck Tumors (HNT)
Introduction. Lymphomas are a heterogenic group of tumors of the lymphatic and hematopoietic systems, and in many cases tumor process develops in the area of the head and neck including skin and mucosa, orbit, nasal cavity and paranasal sinuses, oral cavity, oropharynx, salivary glands, thyroid, and cervical lymph nodes. Differential diagnosis of lymphomas of the head and neck is complicated because it can be accompanied by another non-tumor pathology. High heterogeneity of lymphomas of the head and neck requires structurization of knowledge on their epidemiological and clinical manifestations.The study objective is to optimize early diagnosis as it allows to significantly increase cancer alertness in local practitioners, oncologists, diagnosis specialists and, in turn, to decrease verification frequency in generalized disease processes. Study of clinical characteristics of lymphoproliferative disorders of the head and neck leads to increased quality of differential diagnosis.Materials and methods. A study of lymphoproliferative disorders affecting head and neck was performed. Study material consisted of data on 174 patients hospitalized at the N.N. Blokhin National medical Research Center of Oncology between 1999 and 2020.Results. Based on the current clinical and morphological classification of lymphoproliferative disorders, data on location of lesions, characteristic signs of extranodal lesions and cervical lymph nodes involvement, as well as methods of diagnosis of lymphomas of the head and neck, are presented.Conclusion. The obtained data helps solve problems of diagnosis of lymphoproliferative disorders affecting the head and neck and serve as a basis for successful, predictable treatment of lymphomas.